Efficient healthcare for children with cancer using telemedicine in Schleswig-Holstei

Not Applicable

• Conditions: C00-C97; Malignant neoplasms

• Registration Number: DRKS00021042
• Lead Sponsor: Dekanat der Medizinischen Fakultät, Christian-Albrechts-Universität zu Kiel

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-04-03
• Study Completion: 2024-05-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 55

Inclusion Criteria

Newly diagnosed malignant disease or malignant disease under Treatment OR condition after allogeneic hematopoietic stem cell Transplantation under drug-immunosuppressive therapy.
AND age = 1 year to 25 years.
AND therapy Duration from inclusion = 6 months.
AND anticipated high-frequency contact phases ( = 2 doctor-patient contacts per week during therapy).
AND internet access at home.

Exclusion Criteria

Inclusion criteria not available AND/OR poor language skills which do not allow for a video-/audio conference

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Statistical evidence of equivalence of telemedical support regard to severe complications compared to on-site visits. Therefore, the cumulative score of severe complications (NCI-CTCAE) is measured after 3 and 6 months.

Secondary Outcome Measures

Name	Time	Method
Proof that the time-to-antibiotic” is not prolonged by the telemedical intervention compared to on-site visits<br><br>AND<br><br>Proof that patients and their families experience improvements in their health care and health status using telemedicine. PREMS and PROMS are recorded.